Literature DB >> 18854932

Successful treatment of a patient with severe pulmonary hypertension due to perivalvular leakage at aortic and mitral positions after aortic and mitral valve replacement.

Takashi Miura1, Hiroshi Nishida, Akihiko Kawai, Tomohiro Maeda, Hiromi Kurosawa, Hitoshi Koyanagi.   

Abstract

A 33-year-old-man had severe secondary pulmonary hypertension due to perivalvular leakage at the aortic and mitral positions after aortic and mitral valve replacement. Preoperative cardiac catheterization revealed pulmonary artery pressure of 105/45 mmHg and pulmonary vascular resistance of 929 dynes.s.cm(-5) To save the patient, we performed aortic and mitral valve re-replacement, and tricuspid annuloplasty. After surgery, selective pulmonary vasodilators, beraprost sodium, inhaled nitric oxide, and intravenous prostaglandin (PG) I(2) were administered because of persistent severe pulmonary hypertension. Cardiac catheterization on postoperative day 58 showed that the pulmonary artery pressure and pulmonary vascular resistance had decreased to 40/20 mmHg and 87.7 dynes x s x cm(-5), respectively The simultaneous use of inhaled nitric oxide, intravenous PGI(2), and oral beraprost sodium might be useful for treating postoperative persistent pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854932     DOI: 10.1007/s11748-008-0283-2

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  10 in total

Review 1.  Release of vasoactive substances during cardiopulmonary bypass.

Authors:  S W Downing; L H Edmunds
Journal:  Ann Thorac Surg       Date:  1992-12       Impact factor: 4.330

2.  Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.

Authors:  C Frostell; M D Fratacci; J C Wain; R Jones; W M Zapol
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

3.  Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group.

Authors:  A Costard-Jäckle; M B Fowler
Journal:  J Am Coll Cardiol       Date:  1992-01       Impact factor: 24.094

4.  Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.

Authors:  K K Meja; P J Barnes; M A Giembycz
Journal:  Br J Pharmacol       Date:  1997-09       Impact factor: 8.739

5.  Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1.

Authors:  Kensuke Egashira
Journal:  Hypertension       Date:  2002-12-30       Impact factor: 10.190

6.  Modulation of cytokine release from mononuclear cells by prostacyclin, IL-4 and IL-13.

Authors:  W Luttmann; V Herzog; H Matthys; K H Thierauch; J C Virchow; C Kroegel
Journal:  Cytokine       Date:  1999-02       Impact factor: 3.861

7.  Comparison of the acute pulmonary vasodilating effect of beraprost sodium and nitric oxide in congenital heart disease.

Authors:  Kritvikrom Durongpisitkul; Duangmanee Laoprasitiporn; Thanarat Layangool; Rekwan Sittiwankul; Mannat Panamonta; Pirapat Mokrapong
Journal:  Circ J       Date:  2005-01       Impact factor: 2.993

8.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management.

Authors:  D L Moraes; W S Colucci; M M Givertz
Journal:  Circulation       Date:  2000-10-03       Impact factor: 29.690

9.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J D Roberts; D M Polaner; P Lang; W M Zapol
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

10.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Authors:  R J Barst; L J Rubin; W A Long; M D McGoon; S Rich; D B Badesch; B M Groves; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; L M Clayton; M M Jöbsis; S D Blackburn; D Shortino; J W Crow
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.